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Received September 1, 2011; accepted September 15, 2011AbstractBackground: Anti-Mullerian hormone (AMH), which is secreted by preantral and small antral follicles, has been found to be a valuable marker
of ovarian reserve. The purpose of this study was to determine age-related changes in AMH levels that occur in Taiwanese women and to
determine whether measuring AMH is a highly sensitive and specific tool for diagnosing polycystic ovarian syndrome (PCOS) in Taiwanese
women.
Methods: A group of 59 healthy, fertile, regularly cycling women, a second group of seven patients with premature ovarian failure or menopause,
and a third group of 45 PCOS patients were enrolled. Serum AMH concentrations were measured using an enzyme-linked immunosorbent assay.
Results: AMH levels in healthy fertile women with regular menstrual cycles demonstrated an age-related decline, with a rapid drop between
30e40 years of age that was followed by a slow decrease after 40 years old. All patients with premature ovarian failure and menopause had
undetectable AMH levels. AMH levels in PCOS patients were found to be significantly higher than those measured in healthy fertile controls.
The sensitivity and specificity of AMH for detecting PCOS in patients aged 29e38 years were calculated to be 74% and 79%, respectively, using
an AMH cut-off value of 3.5 ng/mL.
Conclusion: Here, we provide data on Taiwanese women that demonstrate age-related decline in AMH levels and establish an AMH-based
method for detecting PCOS, which may be used as reference data for future AMH studies on Taiwanese women.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Anti-Mullerian hormone (AMH), a hormone originally
known to inhibit the development of Mullerian ducts in male
embryos, has been shown to be an excellent marker of ovarian
reserve in women.1 AMH is secreted by the granulosa cells of
the preantral and small antral follicles and inhibits the initial* Corresponding author. Dr. Kuan-Chong Chao, Department of Obstetrics
and Gynecology, Taipei Veterans General Hospital, 201 Section 2, Shih-Pai
Road, Taipei 112, Taiwan, ROC.
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doi:10.1016/j.jcma.2011.12.007and cyclic recruitment of follicles.2 Serum AMH declines as
age increases in women over 25 years of age,3 and has been
shown to be as effective of a predictor of the ovarian response
during controlled ovarian hyperstimulation as antral follicle
counts (AFCs).4 Moreover, serum AMH exhibits less intra-
and intercycle variation than AFCs, suggesting that AMH
may be a more reliable means of assessing ovarian reserve.5
However, age-related changes in serum AMH levels in
Taiwanese women have not been established.
The expression of AMH can first be detected in human fetal
ovaries at 36 weeks of gestation.6 AMH shows a rise in the
weeks following birth and reaches its highest level afterhinese Medical Association. All rights reserved.
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and become undetectable after menopause.4 This decline in
AMH levels reflects the decrease in the number of follicles and
the resulting reduction in reproductive capacity.7 Several studies
have suggested that a single AMH measurement may be a good
predictor of the onset of menopause in aging women.8e10
Polycystic ovary syndrome (PCOS) is characterized by
chronic oligoanovulation, excessive androgen, and enlarged
polycystic ovaries, and women with PCOS are at greater risk
for the development of diabetes, cardiovascular disease, and
ovarian hyperstimulation syndrome during ovarian stimula-
tion.4,11 Because women with PCOS show an increased
number of antral follicles, circulating AMH levels in these
women are two to three times higher than levels in healthy
controls.12 Measuring AMH has been found to be a useful
diagnostic marker for PCOS.13 However, the AMH-based
diagnostic criteria for PCOS in Taiwanese women remain to
be determined.
The purpose of this study was to establish the age-related
changes in AMH levels that occur in Taiwanese women of
reproductive age and to determine if AMH measurement is
a highly sensitive and specific tool for diagnosing PCOS in
Taiwanese women. Our results may provide a basis for the
application of AMH measurement in Taiwanese women in
the field of reproductive medicine.
2. Methods2.1. SubjectsIn order to determine age-related changes in AMH levels
that occur in healthy, fertile Taiwanese women and in women
with premature ovarian failure or menopause and the sensi-
tivity and specificity of AMH for diagnosing PCOS, we
recruited three types of patients. This study was approved by
the ethics committee of Taipei Veterans Hospital, and informed
consent was obtained from all participating patients.
A group of 59 healthy, fertile, regularly cycling women
aged 26e49 years was enrolled from the community, with all
subjects meeting the following criteria: 1) having at least one
natural pregnancy carried to term; 2) regular menstrual cycle
with an interval of 21e35 days; 3) no medical history of
hirsutism or severe acne; 4) no evidence of endocrine disease;
5) no history of ovarian abnormalities; 6) no history of ovarian
or uterine surgery; and 7) no history of taking medicines that
contained hormones within the previous 2 months.
A second group of seven patients, aged 31e55 years with
premature ovarian failure or menopause, were recruited. All
patients met the following criteria: 1) absence of spontaneous
menstrual bleeding for more than 12 months; 2) serum estra-
diol level <25 pg/mL; and 3) serum follicle-stimulating
hormone level >20 mIU/mL.
A third group of 45 PCOS patients aged 25e40 years was
also recruited. These patients met the Rotterdam criteria, i.e.,
they demonstrated an association between at least two of the
three following features: 1) oligo- or anovulation; 2) clinical
and/or biochemical signs of hyperandrogenism; or 3) polycysticovaries on transvaginal ultrasound; in addition to the exclusion
of related diseases such as hyperprolactinemia, hyperthy-
roidism, congenital adrenal hyperplasia, etc.2.2. Hormonal immunoassaysBlood samples were obtained during the early follicular
phase (days 3e5) from the healthy fertile controls and
PCOS patients. In the case of amenorrhoeic women with
PCOS, intramuscular progesterone (100 mg) or oral medrox-
yprogesterone acetate (10 mg/day for 7 days) was given to
induce withdrawal bleeding. Patients with premature ovarian
failure or menopause were required to give blood samples on
random days. Serum AMH concentrations were assayed using
the ACTIVE MIS/AMH ELISA kit (reference DSL-10-14400;
Diagnostic Systems Laboratories, Inc., Webster, TX, USA)
according to the manufacturer’s instructions. The lowest
detectable level was 0.006 ng/mL. Intra- and interassay coef-
ficients of variation were less than 4.6 and 8.0%, respectively.
Serum concentrations of luteinizing hormone (LH), testos-
terone and dehydroepiandrosterone sulfate (DHEA-S) were
measured using a radioimmunoassay (RIA) (Beckman Coulter,
Inc., Brea, CA, USA).2.3. AnalysisAMH levels are expressed as the means  standard devi-
ation (SD). Statistical significance in experiments with three or
more groups was determined by one-way analysis of variance
using the general linear model, followed by Fisher’s post-hoc
least significant difference test. Statistical significance in
experiments with two groups was determined using the
Student t-test. The sensitivity of AMH for diagnosing PCOS
was defined as the proportion of PCOS patients that were
correctly identified using AMH measurements. The specificity
of AMH for diagnosing PCOS was defined as the proportion
of patients without PCOS that were correctly identified by
AMH testing. However, since there are clinical, biochemical,
and ultrasonic criteria for diagnosing PCOS, our aim was to
increase specificity by using AMH and to keep the sensitivity
as close as possible to the specificity. Correlations were
assessed by calculating the Spearman coefficient.
3. Results3.1. Age-related decline in AMH levelsA total of 59 healthy fertile women were recruited. As
shown in Fig. 1, AMH levels in healthy fertile women with
regular menstrual cycles demonstrated an age-related decline.
Analysis showed that there was a rapid drop in AMH levels
between 30e40 years of age, followed by a slow decrease
after 40 years (Fig. 2; p < 0.05 between the ages of 25e30 and
31e35 years; p < 0.05 between the ages of 31e35 and 36e40
years; p > 0.05 between the ages of 36e40 and 41e45 years).
All patients with premature ovarian failure and menopause had
undetectable AMH levels (Fig. 1).
Fig. 1. Serum anti-Mullerian hormone (AMH) levels in normal fertile controls
and patients with ovarian failure (n ¼ 59 for normal fertile control group;
n ¼ 7 for ovarian failure group).
Fig. 3. Comparison of serum AMH levels in PCOS versus normal fertile
controls (n ¼ 45 for PCOS group; n ¼ 39 for normal fertile controls).
72 K.-C. Chao et al. / Journal of the Chinese Medical Association 75 (2012) 70e743.2. Significantly higher AMH levels in PCOS patientsBecause women with PCOS have an increased number of
antral follicles, serum AMH levels are expected to be higher
in these women. Patients aged 25e40 years who met the
Rotterdam criteria for diagnosing PCOS were recruited. AMH
levels in PCOS patients were found to be higher than those in
healthy fertile controls (Fig. 3). Moreover, the rate of age-
related decline in AMH levels was lower in PCOS patients
compared with that of healthy fertile patients (Fig. 3). Statis-
tical analysis showed that AMH levels in all age-related
subgroups were significantly higher in PCOS patients than
healthy fertile controls (Fig. 4).Fig. 2. Serum AMH concentrations in normal fertile controls of different ages.
The means of groups without the same letter are significantly different (n ¼ 7
for patients aged 25e30 years; n ¼ 12 for patients aged 31e35 years; n ¼ 20
for patients aged 36e40 years; n ¼ 16 for patients aged 41e45 years; and
n ¼ 4 for patients aged 46e49 years).In patients with PCOS, AMH levels were positively
correlated with LH (r ¼ 0.297, p < 0.001), testosterone
(r ¼ 9.365, p ¼ 0.001), and DHEA-S (r ¼ 0.421, p ¼ 0.016),
but the correlation between AMH levels and body mass index
(BMI) was not statistically significant (r ¼ -0.242, p ¼ 0.064).
To calculate the sensitivity and specificity of AMH for
diagnosing PCOS, the age factor was controlled by narrowing
the age range to 29e38 years (the mean ages of the control
and PCOS groups were 33.25  3.04 and 32.32  2.93 years,
respectively; p ¼ 0.257; n ¼ 24 for the control group and
n ¼ 31 for the PCOS group). The sensitivity and specificity of
AMH for diagnosing PCOS in patients aged 29e38 years were
calculated to be 74% and 79%, respectively, using an AMH
cut-off value of 3.5 ng/mL.Fig. 4. Statistical analysis of serum AMH concentrations in PCOS versus
normal fertile control patients in different age subgroups (n ¼ 24 for PCOS
patients aged 25e30 years; n ¼ 7 for normal fertile controls aged 25e30
years; n ¼ 14 for PCOS patients aged 31e35 years; n ¼ 12 for normal fertile
controls aged 31e35 years; n ¼ 7 for PCOS patients aged 36e40 years; and
n ¼ 20 for normal fertile controls aged 36e40 years). * p < 0.05.
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AMH was first discovered as a secretion from the testis of
a male fetus that induced regression of the Mullerian ducts.14
Later, AMH was found to be produced by the granulosa cells
of preantral and small antral follicles in females.15 The AMH
level is low in females at birth, rises rapidly during 0e3
months and 4e8 years of age, and remains constant during
8e25 years of age, and is followed by a gradual decline after
25 years of age.3 After menopause, AMH levels become
undetectable. Although the age-related decline in AMH levels
has been established in several studies, it has not been deter-
mined in Taiwanese women. In the present study, we recruited
59 healthy, fertile, regularly cycling Taiwanese women aged
26e49 years and established age-related changes in AMH
levels. Using these reference data as the control, we found that
AMH levels in PCOS patients were significantly higher. The
sensitivity and specificity of AMH for detecting PCOS in
patients aged 29e38 years were calculated to be 74% and
79%, respectively, using an AMH cut-off value of 3.5 ng/mL.
AMH is a 140-kilodalton glycoprotein homodimer that
belongs to the transforming growth factor family.4 In females,
AMH inhibits the initial and cyclic recruitment of follicles.2
Circulating AMH is solely of ovarian origin in women, and
AMH levels become undetectable 3e5 days after oophorec-
tomy.16 Serum AMH levels are stable throughout the menstrual
cycle and are unmodified by pregnancy, gonadotropin-releasing
hormone treatment, and the administration of short-term oral
contraceptives, makingAMH an ideal marker of ovarian reserve.
In fact, AMH and antral follicle counts have been accepted by
most reproductive endocrinologists as the best methods for
testing ovarian reserve.1 AMH measurement may be superior to
AFCs because it is less operator-dependent and can be per-
formed on any day of the menstrual cycle. In this study, we
found that there was a quick decline in AMH levels between
30e40 years of age that was followed by a gradual decrease after
40 years of age. The age-related decline in AMH levels for
Taiwanese women found in this study can be utilized by future
studies that involve AMH measurement in Taiwanese women.
The serum AMH level, when measured at a certain age, has
been used to predict the age of menopause.8e10 The AMH-
based prediction of age at menopause can be utilized for
reproductive planning. Moreover, it may be useful for
choosing treatment strategies for gynecological diseases. In
women with severe endometriosis who do not desire further
pregnancies, for example, the selection of treatments that
require a definitive hysterectomy versus other medical thera-
pies may depend on when the patient will go through meno-
pause, which could be predicted by AMH measurement. More
normal fertile women and menopausal women need to be
enrolled in additional studies in order to predict the age of
menopause onset in Taiwanese women.
In this study, AMH levels in PCOS women were found to
be approximately three-fold higher that those of healthy fertile
control. Although the increase in AMH levels in PCOS women
was thought to be due to the increase in small antral follicles,
a recent study showed that AMH production is 75 times higherper granulosa cell in PCOS patients than in granulosa cells in
normal ovaries.17 Furthermore, AMH concentrations in the
follicular fluid were five times higher in the follicles of women
with anovulatory PCOS compared with women who were
ovulatory.18 In this study, the rate of age-related decline in
AMH concentrations was found to be smaller in PCOS
patients compared with healthy fertile patients. Whether or not
the aforementioned finding is due to a slower depletion of the
follicular pool in PCOS patients requires further research. The
sensitivity and specificity of AMH-based detection of PCOS in
Taiwanese women aged 29e38 years were calculated to be
74% and 79%, respectively, using an AMH cut-off value of
3.5 ng/mL. Whether it is helpful or not to use AMH as
a screening tool for PCOS requires future investigations.
Racial difference in the serum levels of AMH have been
reported in the literature.19 Compared with white women,
AMH concentrations are lower among black (25.2% lower)
and Hispanic (24.6% lower) women, following adjustment
for other variables. Our data showed that AMH values in
Taiwanese women were similar to or slightly higher than those
of white women that have been reported in previously pub-
lished articles, but variations in different AMH measurement
techniques used by differ laboratories could result in different
results, and other confounding variables will have to be
controlled in future studies. AMH levels were also reported to
be significantly higher in PCOS patients in studies conducted
in France, Finland, and other countries, indicating that higher
AMH values in women with PCOS may be a universal finding
among different races.11e13
In conclusion, we have provided data on Taiwanese women
that demonstrate an age-related decline in AMH levels and
establish an AMH-based method for diagnosing PCOS, which
may be used as reference data for future AMH studies on
Taiwanese women. Future studies are required to evaluate the
value of a single AMH measurement for the prediction of the
age of menopause onset.
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